Abstract： Objective： To observe the clinical effect of Qigui Erbai tang combined with valsartan capsules for chronic glomerulonephritis. Methods： A total of 116 cases of patients with chronic glomerulonephritis were selected as the study objects，and were divided into the observation group and the control group according to the random number table method， 58 cases in each group. The control group was given the oral administration of valsartan capsules，and the observation group was additionally given the oral administration of Qigui Erbai tang based on the treatment of the control group. The clinical effect was compared between the two groups. Urinary protein，the indexes of the lung function[blood urea nitrogen(BUN)，plasma albumi(Alb)， serum creatinine(SCr)]， as well as levels of plasminogen activator inhibitor- 1(PAI- 1)， tissue- plasminogen activator(t- PA)，and cystatin C(Cys C) in serum were detected. The incidence of adverse reactions was observed. Results： The total effective rate was 91.38% in the observation group， and 77.59% in the control group， the difference being significant(P＜0.05). Before treatment， when compared 24- hour urine protein excretion and the indexes of the kidney function between the two groups，there was no significance in the difference(P＞0.05). After treatment，levels of 24-hour urine protein excretion，BUN，and SCr in the two groups were decreased when compared with those before treatment，and the level of Alb was increased；levels of 24-hour urine protein excretion，BUN，and SCr in the observation group were lower than those in the control group，and the level of Alb was higher；differences were significant(P＜0.05). Before treatment， when compared levels of PAI- 1， Cys C， and t- PA in serum between the two groups， there was no significance in the difference(P＞0.05). After treatment，levels of PAI-1 and Cys C in serum in the two groups were decreased when compared with those before treatment，and the level of t-PA was increased；levels of PAI- 1 and Cys C in serum in the observation group were lower than those in the control group，and the level of t-PA was higher；differences were significant(P＜0.05). The incidence of adverse reactions was 8.62% in the observation group， and 17.24% in the control group； there was no significant difference being found in the comparison of the incidence between the two groups(χ 2=1.914， P=0.167>0.05). Conclusion：In the treatment of chronic glomerulonephritis，the therapy of Qigui Erbai tang combined with valsartan capsules achieves an ideal curative effect on reducing the incidence of proteinuria and protecting the kidney function. According to preliminary inference，the reason for effectiveness of the therapy may be related to regulation of levels of PAI- 1，Cys C， and t-PA in serum so as to repair local injured vascular functions of the kidney with medication safety.